Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
← catalyst calendarSponsored by Quoin Pharmaceuticals (industry) · QNRX — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
20estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-14 | actual | When the study began enrolling |
| Primary completion | 2025-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Netherton Syndrome
Intervention
- Drug: QRX003, 4% Lotion
Primary outcomes
what the primary-completion date above is the date OFProportion of subjects with 1-point reduction on IGA
measured Up to week 16
Proportion of subjects with 2-point reduction on IGA
measured Up to week 16
NS surface area change
measured Up to week 16
WI-NRS score change
measured Up to week 16
Assessment of subject satisfaction with treatment based on TSQM
measured Up to week 16
Proportion of subjects requiring rescue therapy
measured Up to week 16
Safety Assessment-AEs
measured Up to week 16
Safety Assessment-LSRs
measured Up to week 16
Permalink · QNRX's whole pipeline · Catalyst calendar · Every registered study · What changed